Found 336 hits.
| 135 | Krause, K., Weller, K., Stefaniak, R., Wittkowski, H., Altrichter, S., Siebenhaar, F., Zuberbier, T., and Maurer, M.+: Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: An open-label study. Allergy 2012: 67; 943-950. IF: 6.27 |
| 272 | Garbani, M., Xia, W., Rhyner, C., Prati, M., Scheynius, A., Malissen, B., Engqvist, H., Maurer, M. Crameri, R., and Terhorst, D.: Allergen-loaded strontium-doped hydroxyapatite spheres improve allergen-specific immunotherapy in mice. Allergy 2017: 72; 570-578. IF: 6.05 |
| 218 | Serra-Pages, M., Torres, R., Plaza, J., Herrerias, A., Costa-FarrĆ©, C., JimĆ©nez, M., Maurer, M.Ā Picado, C., and de Mora, F.+: Activation of the prostaglandin E2 receptor EP2 prevents house dust mite-induced airway hyperresponsiveness and inflammation by restraining mast cells activity. Clin. Exp. Allergy 2015: 45; 1590-1600. IF: 5.58 |
o.218
| 380 | Folkerts, J., Gaudenzio, N.,Ā Maurer, M., Hendriks, R. W., Stadhouders, R. Tam, S. Y., and Galli, S. J.+: Rapid identification of human mast cell degranulation regulators using functional genomics coupled to high-resolution confocal microscopy. Nat. Protoc. 2020: 15; 1285-1310. IF: 13.49 |
o.380
| 101. | Mitchell, S., Balp, M. M., Samuel, M., McBride, D., and Maurer, M.: Systematic review of treatments for chronic spontaneous urticaria with inadequate response to licensed first-line treatments. Int. J. Dermatol. 2015: 54; 1088-1104. IF: 1.41 |
r.101
| 223 | Kay, A. B.+, Clark, P.,Ā Maurer, M.Ā and Ying, S.: Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (āidiopathicā) urticaria. Brit. J. Dermatol. 2015: 172; 1294-1302. IF: 4.31 |
| 168. | Metz, M.+ and Maurer, M.: Use of biologics in chronic spontaneous urticaria ā beyond omalizumab therapy? Allergol. Select. 2021: 5; 89-95. IF: N/A |
r.168
| 27 | Botchkarev, V. A., Komarova, E. A., Siebenhaar, F., Botchkareva, N. V., Komarov, P. G.,Ā Maurer, M.Ā Gilchrest, B. A., and Gudkov, A. V.+: p53 is essential for chemotherapy-induced hair loss. Cancer Res. 2000: 60; 5002-5006. IF: 8.46 |
o.027
| 28 | Botchkarev, V. A.+, Komarova, E. A, Siebenhaar, F., Botchkareva, N. V., Sharov, A. A., Komarov, P. G.,Ā Maurer. M., Gudkov, A. V., and Gilchrest, B. A.: p53 involvement in the control of murine hair follicle regression. Am. J. Pathol. 2001: 158; 1913-1919. IF: 7.1 |
o.028
| 148 | Woidacki, K., Popovic, M., Metz, M., Schumacher, A., Linzke, N., Teles, A., Poirier, F., Fest, S., Jensen, F., Rabinovich, G. A., Maurer, M., and Zenclussen, A. C.+: Mast cells rescue implantation defects caused by c-kit deficiency. Cell Death. Dis. 2013: 4; e462. IF: 5.18 |
o.148